The ORR among the patients with EGFR+ NSCLC with ≥ 25% of tumor cells expressing PD-L1 remained encouraging (12.2%) relative to that (4%) among patients with < 25% PD-L1 expression (92). This evidence concerns the gene CD274 and non-small cell lung carcinoma.